GSK’s Eltrombopag Improves ITP In Phase II Results
This article was originally published in The Pink Sheet Daily
Executive Summary
The thrombocytopenia therapy entered Phase III in February.
You may also be interested in...
GSK’s Promacta Effective In Raising Platelet Count In HCV-Associated Thrombocytopenia, Phase II Data Show
Results published in the New England Journal of Medicine demonstrate 95 percent of hepatitis C patients with thrombocytopenia taking 75 mg dose of eltrombopag once daily had elevated platelet counts.
GSK’s Promacta Effective In Raising Platelet Count In HCV-Associated Thrombocytopenia, Phase II Data Show
Results published in the New England Journal of Medicine demonstrate 95 percent of hepatitis C patients with thrombocytopenia taking 75 mg dose of eltrombopag once daily had elevated platelet counts.
MGI Pharma Boosts Hematology Pipeline With AkaRx Agreement
Phase II thrombocytopenia candidate AKR-501 has revenue potential in excess of $1 billion in the U.S., MGI says.